Skip to main content

Table 1 Characteristics of patients in the training cohort and the validation cohort

From: Nomogram-based parameters to predict overall survival in a real-world advanced cancer population undergoing palliative care

Clinicopathological features Training cohort Validation cohort P value
No. of patients 247 131  
Sex
 Male 133(53.85%) 76(58.02%) 0.4379
 Female 114(46.15%) 55(41.98%)  
Age
 <70y 162(65.59%) 94(71.76%) 0.2222
 > = 70y 85(34.41%) 37(28.24%)  
Tumor stage
 III 15(6.07%) 8(6.11%) 0.9895
 IV 232(93.93%) 123(93.89%)  
Primary tumor site
 Gastrointestinal tumors 125(50.61%) 73(55.73%) 0.1352
 Thoracic cancers 66(26.72%) 20(15.27%)  
 Urogenital neoplasms 34(13.77%) 25(19.08%)  
 Head and neck neoplasms 10(4.05%) 6(4.58%)  
 Other tumors 12(4.86%) 7(5.34%)  
Concomitant disease
 No 138(55.87%) 91(69.47%) 0.0101
 Yes 109(44.13%) 40(30.53%)  
Nutritional status
 Normal 71(28.98%) 36(27.69%) 0.7928
 Abnormal 174(71.02%) 94(72.31%)  
Hospital stay
 <=14d 131(53.04%) 74(56.49%) 0.5215
 >14d 116(46.96%) 57(43.51%)  
 KPS 60(10–90) 60(10–90) 0.1192
Body mass index, kg/m2 21.10(12.62–35.38) 20.80(13.67–34.05) 0.5285
Total bilirubin, umol/L 11.45(3.2–920) 11.95(2.3–389.3) 0.7913
Alkaline phosphatase, U/L 122.15(39.8–2116.1) 120.85(37.1–1342.6) 0.4955
ALT, U/L 17.85(5–914.2) 19.15(5–1156) 0.9394
AST, U/L 25.25(4.9–2435.5) 28.55(8.6–1041.4) 0.9627
Lactate dehydrogenase, U/L 234(81–2651) 217(85–2101) 0.4242
Cystatin-C, mg/L 1.25(0.65–5.7) 1.135(0.57–4) 0.0218
Creatinine, umol/L 67(26–468) 63(32–406) 0.1013
Platelet count, No. × 109/L 217(10–872) 201.5(26–753) 0.1819
Neutrophil count, No. × 109/L 6.2(1–91.7) 5.55(1.2–96) 0.0535
Lymphocyte count, No. ×109/L 1.1(0.1–32.1) 1.1(0.3–4.2) 0.6950
Hemoglobin, g/L 107(42–169) 109.5(32–171) 0.5162
CEA, ng/ml 4.76(0.32–929.1) 3.83(0.44–975.1) 0.4807
Albumin, g/L 33.6(17.3–48.4) 34.5(13.5–48.4) 0.1863
Uric acid, umol/L 314.5(71.0–1560.0) 323(70–1073) 0.6762
  1. Abbreviation: KPS karnofsky performance status score, CEA carcinoembryonic antigen, ALT Glutamic-pyruvic transaminase, AST Glutamic-oxalacetic transaminase